AI 본문요약

엑셀 다운로드 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

참고문헌 (61)

1. 1 Theill LE Boyle WJ Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002 20 795 823 10.1146/annurev.immunol.20.100301.064753 11861618 

   상세보기

2. 2 Boyle WJ Simonet WS Lacey DL. Osteoclast differentiation and activation. Nature 2003 423 337 342 10.1038/nature01658 12748652 

   상세보기

3. 3 Karsenty G Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002 2 389 406 10.1016/S1534-5807(02)00157-0 11970890 

   상세보기

4. 4 Soltanoff CS Yang S Chen W Li YP. Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr 2009 19 1 46 10.1615/CritRevEukarGeneExpr.v19.i1.10 19191755 

   상세보기

5. 5 Huang W Yang S Shao J Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007 12 3068 3092 10.2741/2296 17485283 

   상세보기

6. 6 Kogianni G Noble BS. The biology of osteocytes. Curr Osteoporos Rep 2007 5 81 86 10.1007/s11914-007-0007-z 17521510 

   상세보기

7. 7 Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 115 3318 3325 10.1172/JCI27071 16322775 

   상세보기

8. 8 Ng KW. Future developments in osteoporosis therapy. Endocr Metab Immune Disord Drug Targets 2009 9 371 384 10.2174/187153009789839192 19857200 

   상세보기

9. 9 Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994 843 1 129 7941614 

10. 10 National Osteoporosis Foundation. Learn about osteoporosis. Available from: http://www.nof.org/node/40. 

11. 11 World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Available from: http://www.who.int/chp/topics/Osteoporosis.pdf. 

12. 12 Lau RY Guo X. A review on current osteoporosis research: with special focus on disuse bone loss. J Osteoporos 2011 2011 293808 21876833 

13. 13 Narducci P Nicolin V. Differentiation of activated monocytes into osteoclast-like cells on a hydroxyapatite substrate: an in vitro study. Ann Anat 2009 191 349 355 10.1016/j.aanat.2009.02.009 19447592 

    상세보기

14. 14 Baron R Neff L Vignery A. Differentiation and functional characteristics of osteoclasts. Bone 1985 6 414 10.1016/8756-3282(85)90385-0 

    상세보기

15. 15 Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165 176 10.1016/S0092-8674(00)81569-X 9568710 

    상세보기

16. 16 Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett T et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309 319 10.1016/S0092-8674(00)80209-3 9108485 

    상세보기

17. 17 Yasuda H Shima N Nakagawa N Yamaguchi K Kinosaki M Mochizuki S Tomoyasu A Yano K Goto M Murakami A et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998 95 3597 3602 10.1073/pnas.95.7.3597 9520411 

    상세보기

18. 18 Du J Cheng B Zhu X Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. J Immunol 2011 187 942 950 10.4049/jimmunol.1002579 21666059 

    상세보기

19. 19 Koga T Inui M Inoue K Kim S Suematsu A Kobayashi E Iwata T Ohnishi H Matozaki T Kodama T et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004 428 758 763 10.1038/nature02444 15085135 

    상세보기

20. 20 Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001 142 5050 5055 10.1210/en.142.12.5050 11713196 

    상세보기

21. 21 Hsu H Lacey DL Dunstan CR Solovyev I Colombero A Timms E Tan HL Elliott G Kelley MJ Sarosi I et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999 96 3540 3545 10.1073/pnas.96.7.3540 10097072 

    상세보기

22. 22 Lomaga MA Yeh WC Sarosi I Duncan GS Furlonger C Ho A Morony S Capparelli C Van G Kaufman S et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999 13 1015 1024 10.1101/gad.13.8.1015 10215628 

    상세보기

23. 23 Boyce BF Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007 9 Suppl 1 S1 10.1186/ar2165 17634140 

    상세보기

24. 24 Sundaram K Nishimura R Senn J Youssef RF London SD Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007 313 168 178 10.1016/j.yexcr.2006.10.001 17084841 

    상세보기

25. 25 Jayakumar P Di Silvio L. Osteoblasts in bone tissue engineering. Proc Inst Mech Eng H 2010 224 1415 1440 10.1243/09544119JEIM821 21287829 

    상세보기

26. 26 Derynck R Zhang Y. Intracellular signalling: the mad way to do it. Curr Biol 1996 6 1226 1229 10.1016/S0960-9822(96)00702-6 8939556 

    상세보기

27. 27 Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994 8 133 146 10.1101/gad.8.2.133 8299934 

    상세보기

28. 28 Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996 85 947 950 10.1016/S0092-8674(00)81296-9 8674122 

    상세보기

29. 29 Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev 1994 4 737 744 10.1016/0959-437X(94)90141-O 7849513 

    상세보기

30. 30 Berridge M. Cell signaling biology. Available from: http://www.biochemj.org/csb. 

31. 31 Chen D Zhao M Mundy GR. Bone morphogenetic proteins. Growth Factors 2004 22 233 241 10.1080/08977190412331279890 15621726 

    상세보기

32. 32 Yamashita H Ten Dijke P Heldin CH Miyazono K. Bone morphogenetic protein receptors. Bone 1996 19 569 574 10.1016/S8756-3282(96)00259-1 8968021 

    상세보기

33. 33 Merck. Fosamax (alendronate sodium) tablets and oral solution prescribing information. Merck Whitehouse Station 2011 

34. 34 Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) injection prescribing information. Novartis Pharmaceuticals Corporation East Hanover 2011 

35. 35 Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009 360 89 90 10.1056/NEJMc0808738 19118315 

    상세보기

36. 36 Hwang JT Kim SH Lee MS Kim SH Yang HJ Kim MJ Kim HS Ha J Kim MS Kwon DY. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 2007 364 1002 1008 10.1016/j.bbrc.2007.10.125 17971295 

    상세보기

37. 37 Kim DY Park KH Jung MS Huang B Yuan HD Quan HY Chung SH. Ginsenoside Rh2(S) induces differentiation and mineralization of MC3T3-E1 cells through activation of the PKD/AMPK signaling pathways. Int J Mol Med 2011 28 753 759 21769419 

38. 38 Liu J Shiono J Shimizu K Yu H Zhang C Jin F Kondo R. 20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett 2009 19 3320 3323 10.1016/j.bmcl.2009.04.054 19428246 

    상세보기

39. 39 Cheng B Li J Du J Lv X Weng L Ling C. Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways. Food Chem Toxicol 2012 50 1610 1615 10.1016/j.fct.2012.02.019 22386813 

    상세보기

40. 40 Kim DY Park YG Quan HY Kim SJ Jung MS Chung SH. Ginsenoside Rd stimulates the differentiation and mineralization of osteoblastic MC3T3-E1 cells by activating AMP-activated protein kinase via the BMP-2 signaling pathway. Fitoterapia 2012 83 215 222 10.1016/j.fitote.2011.10.017 22061660 

    상세보기

41. 41 Kim DY Jung MS Park YG Yuan HD Quan HY Chung SH. Ginsenoside Rh2(S) induces the differentiation and mineralization of osteoblastic MC3T3-E1 cells through activation of PKD and p38 MAPK pathways. BMB Rep 2011 44 659 664 10.5483/BMBRep.2011.44.10.659 22026999 

    원문보기 상세보기

42. 42 He L Lee J Jang JH Lee SH Nan MH Oh BC Lee SG Kim HH Soung NK Ahn JS et al. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. Bone 2012 50 1207 1213 10.1016/j.bone.2012.03.022 22484180 

    상세보기

43. 43 Li XD Chang B Chen B Liu ZY Liu DX Wang JS Hou GQ Huang DY Du SX. Panax notoginseng saponins potentiate osteogenesis of bone marrow stromal cells by modulating gap junction intercellular communication activities. Cell Physiol Biochem 2010 26 1081 1092 10.1159/000323986 21220939 

    상세보기

44. 44 Li XD Liu ZY Chang B Liu DX Chen B Guo C Wang YG Xu JK Huang DY Du SX. Panax notoginseng saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK and P38 MAPK signaling pathways. Cell Physiol Biochem 2011 28 367 376 10.1159/000331753 21865745 

    상세보기

45. 45 Gong YS Chen J Zhang QZ Zhang JT. Effect of 17beta-oestradiol and ginsenoside on osteoporosis in ovariectomised rats. J Asian Nat Prod Res 2006 8 649 656 10.1080/10286020500246063 17135052 

    상세보기

46. 46 Monroe DG Hawse JR Subramaniam M Spelsberg TC. Retinoblastoma binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation. BMC Musculoskelet Disord 2010 11 104 10.1186/1471-2474-11-104 20509905 

    상세보기

47. 47 Kim KS Pyo SK Sohn EH. Immunomodulation of NK cell activity by red ginseng acidic polysaccharide (RGAP) in ovariectomized rats. J Ginseng Res 2009 33 99 103 10.5142/JGR.2009.33.2.099 

    원문보기 상세보기

48. 48 Yovel G Shakhar K Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol 2001 81 254 262 10.1006/gyno.2001.6153 11330959 

    상세보기

49. 49 Kropotov AV Kolodnyak OL Koldaev VM. Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis. Bull Exp Biol Med 2002 133 252 254 10.1023/A:1015834717178 12360344 

    상세보기

50. 50 Kim HR Cui Y Hong SJ Shin SJ Kim DS Kim NM So SH Lee SK Kim EC Chae SW et al. Effect of ginseng mixture on osteoporosis in ovariectomized rats. Immunopharmacol Immunotoxicol 2008 30 333 345 10.1080/08923970801949125 18569088 

    상세보기

51. 51 Shen Y Li YQ Li SP Ma L Ding LJ Ji H. Alleviation of ovariectomy-induced osteoporosis in rats by Panax notoginseng saponins. J Nat Med 2010 64 336 345 10.1007/s11418-010-0416-7 20376572 

    상세보기

52. 52 Li XD Wang JS Chang B Chen B Guo C Hou GQ Huang DY Du SX. Panax notoginseng saponins promotes proliferation and osteogenic differentiation of rat bone marrow stromal cells. J Ethnopharmacol 2011 134 268 274 10.1016/j.jep.2010.11.075 21167926 

    상세보기

53. 53 Brewer L Williams D Moore A. Current and future treatment options in osteoporosis. Eur J Clin Pharmacol 2011 67 321 331 10.1007/s00228-011-0999-2 21327420 

    상세보기

54. 54 Yuan HD Kim JT Kim SH Chung SH. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 2012 361 27 39 10.5142/jgr.2012.36.1.27 23717101 

    원문보기 상세보기

55. 55 Huang KC Williams WM. The pharmacology of Chinese herbs. CRC Press Boca Raton 1999 

56. 56 Kwak YS Park JD Yang JW. Present and its prospect of red ginseng efficacy research. Food Ind Nutr 2003 8 30 37 

57. 57 Quan LH Cheng LQ Kim HB Kim JH Son NR Kim SY Jin HO Yang DC. Bioconversion of ginsenoside Rd into compound K by Lactobacillus pentosus DC101 isolated from kimchi. J Ginseng Res 2010 34 288 295 10.5142/jgr.2010.34.4.288 

    원문보기 상세보기

58. 58 Shin HY Jeong HJ An HJ Hong SH Um JY Shin TY Kwon SJ Jee SY Seo BI Shin SS et al. The effect of Panax ginseng on forced immobility time & immune function in mice. Indian J Med Res 2006 124 199 206 17015935 

    상세보기

59. 59 Wang W Zhao Y Rayburn ER Hill DL Wang H Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 2007 59 589 601 10.1007/s00280-006-0300-z 16924497 

    상세보기

60. 60 Polan ML Hochberg RB Trant AS Wuh HC. Estrogen bioassay of ginseng extract and ArginMax, a nutritional supplement for the enhancement of female sexual function. J Womens Health (Larchmt) 2004 13 427 430 10.1089/154099904323087114 15186659 

    상세보기

61. 61 Kim NH Lee HM Choi CH Lim SK. Clinical effect of Korean red ginseng on osteoporosis. J Ginseng Res 1998 22 114 121 

저자의 다른 논문 :

김연주 (13) 양동욱 (5) 양덕춘 (66)